A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Clinical Efficacy, Safety, and Immunogenicity of a Human Cocaine Vaccine (TA-CD) in the Treatment of Cocaine Dependence

The purpose of this study is to test the efficacy of a newly developed active vaccine against cocaine (TA-CD).

开始日期2010-08-01

申办/合作机构

Baylor College of Medicine

[+8]

100 项与 Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical) 相关的临床结果

登录后查看更多信息

100 项与 Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical) 相关的转化医学

登录后查看更多信息

100 项与 Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical) 相关的专利（医药）

登录后查看更多信息

项与 Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical) 相关的文献（医药）

2021-12-01·CARTILAGE3区 · 医学

The Viability and Anti-Inflammatory Effects of Hyaluronic Acid-Chitlac-Tracimolone Acetonide- β-Cyclodextrin Complex on Human Chondrocytes

3区 · 医学

Article

作者: Brun, Paola ; Faggian, Alessia ; Elia, Rossella ; Tarricone, Elena ; Ruggieri, Pietro ; Mattiuzzo, Elena ; Pozzuoli, Assunta

Objective To compare the effects of the complex triamcinolone acetonide-hydroxypropyl-β-cyclodextrin (TA-CD) on in vitro inflamed primary human articular chondrocytes in the presence or absence of the mixture hyaluronic acid-Chitlac, a lactose-modified chitosan (HA-CTL). Design Changes in cell viability and pro-inflammatory cytokines gene expression were analyzed in human chondrocytes using an in vitro model of macrophage-mediated inflammation. Human monocytes U937 were differentiated to macrophages by phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharides (LPS). The anti-inflammatory effects of the complex TA-CD and HA-CTL mixture were assessed on chondrocytes exposed for 24 hours to U937 conditioned medium (CM), by quantitative polymerase chain reaction analysis. Results The TA-CD viability was enhanced by the presence of the HA-CTL mixture in chondrocyte cultures. The exposure of cells to CM significantly increased interleukin-1β and interleukin-6 gene expression, and when the complex TA-CD was added to the inflamed cells, gene transcription of cytokines was restored to near baseline values, both in the presence or in the absence of HA-CTL mixture. Conclusion The addition of HA-CTL mixture significantly attenuated cytotoxicity induced by TA and preserved the anti-inflammatory effects, thus confirming the chondroprotective role of the HA-CTL mixture.

2021-07-01·Journal of Controlled Release1区 · 医学

Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration

1区 · 医学

Article

作者: Lutty, Gerard A ; Bhutto, Imran A ; Kambhampati, Siva P ; Ho, Katie ; Kannan, Rangaramanujam M ; Wu, Tony ; McLeod, D Scott

Inflammation and neovascularization are key pathological events in human age-related macular degeneration (AMD). Activated microglia/macrophages (mi/ma) and retinal pigmented epithelium (RPE) play an active role in every stage of disease progression. Systemic therapies that can target these cells and address both inflammation and neovascularization will broaden the impact of existing therapies and potentially open new avenues for early AMD where there are no viable therapies. Utilizing a clinically relevant rat model of AMD that mirrors many aspects that of human AMD pathological events, we show that systemic hydroxyl-terminated polyamidoamine dendrimer-triamcinolone acetonide conjugate (D-TA) is selectively taken up by the injured mi/ma and RPE (without the need for targeting ligands). D-TA suppresses choroidal neovascularization significantly (by >80%, >50-fold better than free drug), attenuates inflammation in the choroid and retina, by limiting macrophage infiltration in the pathological area, significantly suppressing pro-inflammatory cytokines and pro-angiogenic factors, with minimal side effects to healthy ocular tissue and other organs. In ex vivo studies on human postmortem diabetic eyes, the dendrimer is also taken up into choroidal macrophages. These results suggest that the systemic hydroxyl dendrimer-drugs can offer new avenues for therapies in treating early/dry AMD and late/neovascular AMD alone, or in combination with current anti-VEGF therapies. This hydroxyl dendrimer platform but conjugated to a different drug is undergoing clinical trials for severe COVID-19, potentially paving the way for faster clinical translation of similar compounds for ocular and retinal disorders.

2021-02-01·Advanced Therapeutics

Dendrimer‐Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy

Article

作者: Duh, Elia J. ; Lee, Grace ; Zhou, Lingli ; Kannan, Rangaramanujam M. ; Cho, Hongkwan ; Kambhampati, Siva P. ; Xie, Yangyiran ; Hui, Qiaoyan ; Lai, Michael J.

AbstractDiabetic retinopathy (DR) is the leading cause of blindness in working‐age adults. Severe visual loss in DR is primarily due to proliferative diabetic retinopathy, characterized by pathologic preretinal angiogenesis driven by retinal ischemia. Microglia, the resident immune cells of the retina, have emerged as a potentially important regulator of pathologic retinal angiogenesis. Corticosteroids including triamcinolone acetonide (TA), known for their antiangiogenic effects, are used in treating retinal diseases, but their use is significantly limited by side effects including cataracts and glaucoma. Generation‐4 hydroxyl polyamidoamine dendrimer nanoparticles are utilized to deliver TA to activated microglia in the ischemic retina in a mouse model of oxygen‐induced retinopathy (OIR). Following intravitreal injection, dendrimer‐conjugated TA (D‐TA) exhibits selective localization and sustained retention in activated microglia in disease‐associated areas of the retina. D‐TA, but not free TA, suppresses inflammatory cytokine production, microglial activation, and preretinal neovascularization in OIR. In addition, D‐TA, but not free TA, ameliorates OIR‐induced neuroretinal and visual dysfunction. These results indicate that activated microglia are a promising therapeutic target for retinal angiogenesis and neuroprotection in ischemic retinal diseases. Furthermore, dendrimer‐based targeted therapy and specifically D‐TA constitute a promising treatment approach for DR, offering increased and sustained drug efficacy with reduced side effects.

100 项与 Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
可卡因相关疾病	临床2期	-	ImmuLogic Pharmaceutical Corp.	-
可卡因相关疾病	临床2期	-	Celtic Pharma GP Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00969878 (TA-CD, CTgov)	临床2期	可卡因相关疾病	300	Placebo Injection (Placebo Injection)	鑰願醖鬱鏇鬱淵壓餘醖(選鏇艱廠範製鑰願鑰鏇) = 簾糧鏇簾網餘獵廠淵範製夢衊願廠簾憲壓艱齋 (齋鹽簾鹽蓋範觸衊襯壓, 築艱獵憲製齋獵夢觸製 ~ 繭積膚鏇夢壓鹽遞顧積) 更多	-	2014-12-12
				TA-CD Vaccination (TA-CD Vaccination)	鑰願醖鬱鏇鬱淵壓餘醖(選鏇艱廠範製鑰願鑰鏇) = 願簾廠顧廠壓網廠壓鹹製夢衊願廠簾憲壓艱齋 (齋鹽簾鹽蓋範觸衊襯壓, 遞鬱糧鹽衊繭襯衊淵鏇 ~ 積願積壓鏇觸繭憲淵餘) 更多